nodes	percent_of_prediction	percent_of_DWPC	metapath
Terazosin—ABCB1—Estramustine—prostate cancer	0.0789	0.2	CbGbCtD
Terazosin—ADRA1B—vas deferens—prostate cancer	0.0536	0.48	CbGeAlD
Terazosin—ABCB1—Cabazitaxel—prostate cancer	0.052	0.132	CbGbCtD
Terazosin—ABCB1—Estrone—prostate cancer	0.0508	0.129	CbGbCtD
Terazosin—ABCB1—Ethinyl Estradiol—prostate cancer	0.0453	0.115	CbGbCtD
Terazosin—ABCB1—Conjugated Estrogens—prostate cancer	0.0332	0.0843	CbGbCtD
Terazosin—ABCB1—Mitoxantrone—prostate cancer	0.0302	0.0767	CbGbCtD
Terazosin—ABCB1—Estradiol—prostate cancer	0.0292	0.074	CbGbCtD
Terazosin—ABCB1—Prednisone—prostate cancer	0.0251	0.0637	CbGbCtD
Terazosin—ABCB1—Etoposide—prostate cancer	0.0191	0.0483	CbGbCtD
Terazosin—ABCB1—Docetaxel—prostate cancer	0.0174	0.0442	CbGbCtD
Terazosin—ABCB1—Doxorubicin—prostate cancer	0.013	0.033	CbGbCtD
Terazosin—KCNH6—prostate gland—prostate cancer	0.00845	0.0757	CbGeAlD
Terazosin—KCNH6—renal system—prostate cancer	0.00576	0.0516	CbGeAlD
Terazosin—KCNH7—testis—prostate cancer	0.00523	0.0468	CbGeAlD
Terazosin—ADRA1D—prostate gland—prostate cancer	0.00468	0.042	CbGeAlD
Terazosin—ADRA1D—epithelium—prostate cancer	0.00344	0.0308	CbGeAlD
Terazosin—ADRA1B—renal system—prostate cancer	0.00326	0.0292	CbGeAlD
Terazosin—ADRA1D—urethra—prostate cancer	0.00313	0.0281	CbGeAlD
Terazosin—ADRA1A—prostate gland—prostate cancer	0.00269	0.0241	CbGeAlD
Terazosin—KCNH2—prostate gland—prostate cancer	0.0026	0.0233	CbGeAlD
Terazosin—Prazosin—SLC22A3—prostate cancer	0.00231	0.338	CrCbGaD
Terazosin—KCNH2—seminal vesicle—prostate cancer	0.0022	0.0197	CbGeAlD
Terazosin—ADRA1A—epithelium—prostate cancer	0.00198	0.0177	CbGeAlD
Terazosin—ADRA1A—renal system—prostate cancer	0.00183	0.0164	CbGeAlD
Terazosin—KCNH2—renal system—prostate cancer	0.00177	0.0159	CbGeAlD
Terazosin—KCNH2—urethra—prostate cancer	0.00174	0.0156	CbGeAlD
Terazosin—Prazosin—SLC22A1—prostate cancer	0.00166	0.243	CrCbGaD
Terazosin—KCNH2—bone marrow—prostate cancer	0.00134	0.012	CbGeAlD
Terazosin—KCNH2—testis—prostate cancer	0.00114	0.0103	CbGeAlD
Terazosin—ABCB1—prostate gland—prostate cancer	0.00114	0.0102	CbGeAlD
Terazosin—Doxazosin—CYP2C19—prostate cancer	0.000987	0.145	CrCbGaD
Terazosin—Alfuzosin—CYP3A4—prostate cancer	0.000965	0.141	CrCbGaD
Terazosin—ABCB1—seminal vesicle—prostate cancer	0.000964	0.00864	CbGeAlD
Terazosin—Prazosin—CYP1A1—prostate cancer	0.000906	0.133	CrCbGaD
Terazosin—ABCB1—epithelium—prostate cancer	0.000837	0.0075	CbGeAlD
Terazosin—KCNH2—lymph node—prostate cancer	0.000829	0.00743	CbGeAlD
Terazosin—ABCB1—renal system—prostate cancer	0.000777	0.00696	CbGeAlD
Terazosin—ABCB1—urethra—prostate cancer	0.000763	0.00684	CbGeAlD
Terazosin—ABCB1—bone marrow—prostate cancer	0.000587	0.00526	CbGeAlD
Terazosin—ABCB1—testis—prostate cancer	0.000502	0.0045	CbGeAlD
Terazosin—ABCB1—lymph node—prostate cancer	0.000364	0.00326	CbGeAlD
Terazosin—Dry mouth—Capecitabine—prostate cancer	0.000136	0.000356	CcSEcCtD
Terazosin—Vomiting—Estradiol—prostate cancer	0.000136	0.000356	CcSEcCtD
Terazosin—Gastrointestinal pain—Etoposide—prostate cancer	0.000136	0.000355	CcSEcCtD
Terazosin—Shock—Docetaxel—prostate cancer	0.000136	0.000355	CcSEcCtD
Terazosin—Ill-defined disorder—Prednisone—prostate cancer	0.000135	0.000353	CcSEcCtD
Terazosin—Thrombocytopenia—Docetaxel—prostate cancer	0.000135	0.000353	CcSEcCtD
Terazosin—Rash—Estradiol—prostate cancer	0.000135	0.000353	CcSEcCtD
Terazosin—Dermatitis—Estradiol—prostate cancer	0.000135	0.000352	CcSEcCtD
Terazosin—Confusional state—Capecitabine—prostate cancer	0.000135	0.000352	CcSEcCtD
Terazosin—Tachycardia—Docetaxel—prostate cancer	0.000135	0.000352	CcSEcCtD
Terazosin—Headache—Estradiol—prostate cancer	0.000134	0.000351	CcSEcCtD
Terazosin—Oedema—Capecitabine—prostate cancer	0.000134	0.000349	CcSEcCtD
Terazosin—Angioedema—Prednisone—prostate cancer	0.000133	0.000348	CcSEcCtD
Terazosin—Jaundice—Doxorubicin—prostate cancer	0.000132	0.000344	CcSEcCtD
Terazosin—Anorexia—Docetaxel—prostate cancer	0.000132	0.000344	CcSEcCtD
Terazosin—Malaise—Prednisone—prostate cancer	0.000132	0.000343	CcSEcCtD
Terazosin—Shock—Capecitabine—prostate cancer	0.000132	0.000343	CcSEcCtD
Terazosin—Rhinitis—Epirubicin—prostate cancer	0.000132	0.000343	CcSEcCtD
Terazosin—Abdominal pain—Etoposide—prostate cancer	0.000131	0.000343	CcSEcCtD
Terazosin—Body temperature increased—Etoposide—prostate cancer	0.000131	0.000343	CcSEcCtD
Terazosin—Urinary tract infection—Doxorubicin—prostate cancer	0.000131	0.000343	CcSEcCtD
Terazosin—Conjunctivitis—Doxorubicin—prostate cancer	0.000131	0.000343	CcSEcCtD
Terazosin—Vertigo—Prednisone—prostate cancer	0.000131	0.000342	CcSEcCtD
Terazosin—Thrombocytopenia—Capecitabine—prostate cancer	0.000131	0.000342	CcSEcCtD
Terazosin—Syncope—Prednisone—prostate cancer	0.000131	0.000342	CcSEcCtD
Terazosin—Tachycardia—Capecitabine—prostate cancer	0.000131	0.000341	CcSEcCtD
Terazosin—Pharyngitis—Epirubicin—prostate cancer	0.00013	0.00034	CcSEcCtD
Terazosin—Sweating—Doxorubicin—prostate cancer	0.00013	0.000338	CcSEcCtD
Terazosin—Hyperhidrosis—Capecitabine—prostate cancer	0.000129	0.000337	CcSEcCtD
Terazosin—Oedema peripheral—Epirubicin—prostate cancer	0.000129	0.000337	CcSEcCtD
Terazosin—Hypotension—Docetaxel—prostate cancer	0.000129	0.000337	CcSEcCtD
Terazosin—Loss of consciousness—Prednisone—prostate cancer	0.000128	0.000335	CcSEcCtD
Terazosin—Epistaxis—Doxorubicin—prostate cancer	0.000128	0.000333	CcSEcCtD
Terazosin—Anorexia—Capecitabine—prostate cancer	0.000128	0.000333	CcSEcCtD
Terazosin—Nausea—Estradiol—prostate cancer	0.000127	0.000332	CcSEcCtD
Terazosin—Vomiting—Mitoxantrone—prostate cancer	0.000127	0.000331	CcSEcCtD
Terazosin—Sinusitis—Doxorubicin—prostate cancer	0.000127	0.000331	CcSEcCtD
Terazosin—Convulsion—Prednisone—prostate cancer	0.000127	0.00033	CcSEcCtD
Terazosin—Visual impairment—Epirubicin—prostate cancer	0.000126	0.00033	CcSEcCtD
Terazosin—Rash—Mitoxantrone—prostate cancer	0.000126	0.000329	CcSEcCtD
Terazosin—Dermatitis—Mitoxantrone—prostate cancer	0.000126	0.000328	CcSEcCtD
Terazosin—Musculoskeletal discomfort—Docetaxel—prostate cancer	0.000126	0.000328	CcSEcCtD
Terazosin—Headache—Mitoxantrone—prostate cancer	0.000125	0.000327	CcSEcCtD
Terazosin—Hypotension—Capecitabine—prostate cancer	0.000125	0.000326	CcSEcCtD
Terazosin—Insomnia—Docetaxel—prostate cancer	0.000125	0.000326	CcSEcCtD
Terazosin—Arthralgia—Prednisone—prostate cancer	0.000124	0.000324	CcSEcCtD
Terazosin—Myalgia—Prednisone—prostate cancer	0.000124	0.000324	CcSEcCtD
Terazosin—Paraesthesia—Docetaxel—prostate cancer	0.000124	0.000324	CcSEcCtD
Terazosin—Anxiety—Prednisone—prostate cancer	0.000124	0.000323	CcSEcCtD
Terazosin—Dyspnoea—Docetaxel—prostate cancer	0.000123	0.000321	CcSEcCtD
Terazosin—Somnolence—Docetaxel—prostate cancer	0.000123	0.00032	CcSEcCtD
Terazosin—Discomfort—Prednisone—prostate cancer	0.000123	0.00032	CcSEcCtD
Terazosin—Eye disorder—Epirubicin—prostate cancer	0.000123	0.00032	CcSEcCtD
Terazosin—Hypersensitivity—Etoposide—prostate cancer	0.000123	0.00032	CcSEcCtD
Terazosin—Tinnitus—Epirubicin—prostate cancer	0.000122	0.000319	CcSEcCtD
Terazosin—Musculoskeletal discomfort—Capecitabine—prostate cancer	0.000122	0.000318	CcSEcCtD
Terazosin—Rhinitis—Doxorubicin—prostate cancer	0.000122	0.000317	CcSEcCtD
Terazosin—Dyspepsia—Docetaxel—prostate cancer	0.000122	0.000317	CcSEcCtD
Terazosin—Insomnia—Capecitabine—prostate cancer	0.000121	0.000316	CcSEcCtD
Terazosin—Pharyngitis—Doxorubicin—prostate cancer	0.00012	0.000314	CcSEcCtD
Terazosin—Paraesthesia—Capecitabine—prostate cancer	0.00012	0.000313	CcSEcCtD
Terazosin—Decreased appetite—Docetaxel—prostate cancer	0.00012	0.000313	CcSEcCtD
Terazosin—Oedema peripheral—Doxorubicin—prostate cancer	0.00012	0.000312	CcSEcCtD
Terazosin—Asthenia—Etoposide—prostate cancer	0.000119	0.000311	CcSEcCtD
Terazosin—Dyspnoea—Capecitabine—prostate cancer	0.000119	0.000311	CcSEcCtD
Terazosin—Oedema—Prednisone—prostate cancer	0.000119	0.000311	CcSEcCtD
Terazosin—Anaphylactic shock—Prednisone—prostate cancer	0.000119	0.000311	CcSEcCtD
Terazosin—Fatigue—Docetaxel—prostate cancer	0.000119	0.000311	CcSEcCtD
Terazosin—Nausea—Mitoxantrone—prostate cancer	0.000119	0.00031	CcSEcCtD
Terazosin—Constipation—Docetaxel—prostate cancer	0.000118	0.000308	CcSEcCtD
Terazosin—Pain—Docetaxel—prostate cancer	0.000118	0.000308	CcSEcCtD
Terazosin—Dyspepsia—Capecitabine—prostate cancer	0.000118	0.000307	CcSEcCtD
Terazosin—Pruritus—Etoposide—prostate cancer	0.000118	0.000307	CcSEcCtD
Terazosin—Shock—Prednisone—prostate cancer	0.000117	0.000306	CcSEcCtD
Terazosin—Arrhythmia—Epirubicin—prostate cancer	0.000117	0.000306	CcSEcCtD
Terazosin—Visual impairment—Doxorubicin—prostate cancer	0.000117	0.000305	CcSEcCtD
Terazosin—Tachycardia—Prednisone—prostate cancer	0.000116	0.000303	CcSEcCtD
Terazosin—Decreased appetite—Capecitabine—prostate cancer	0.000116	0.000303	CcSEcCtD
Terazosin—Fatigue—Capecitabine—prostate cancer	0.000115	0.000301	CcSEcCtD
Terazosin—Hyperhidrosis—Prednisone—prostate cancer	0.000115	0.0003	CcSEcCtD
Terazosin—Pain—Capecitabine—prostate cancer	0.000114	0.000298	CcSEcCtD
Terazosin—Constipation—Capecitabine—prostate cancer	0.000114	0.000298	CcSEcCtD
Terazosin—Malnutrition—Epirubicin—prostate cancer	0.000114	0.000298	CcSEcCtD
Terazosin—Feeling abnormal—Docetaxel—prostate cancer	0.000114	0.000297	CcSEcCtD
Terazosin—Diarrhoea—Etoposide—prostate cancer	0.000114	0.000297	CcSEcCtD
Terazosin—Anorexia—Prednisone—prostate cancer	0.000114	0.000296	CcSEcCtD
Terazosin—Eye disorder—Doxorubicin—prostate cancer	0.000113	0.000296	CcSEcCtD
Terazosin—Tinnitus—Doxorubicin—prostate cancer	0.000113	0.000295	CcSEcCtD
Terazosin—Gastrointestinal pain—Docetaxel—prostate cancer	0.000113	0.000295	CcSEcCtD
Terazosin—Flatulence—Epirubicin—prostate cancer	0.000113	0.000294	CcSEcCtD
Terazosin—Tension—Epirubicin—prostate cancer	0.000112	0.000292	CcSEcCtD
Terazosin—Dysgeusia—Epirubicin—prostate cancer	0.000112	0.000292	CcSEcCtD
Terazosin—Nervousness—Epirubicin—prostate cancer	0.000111	0.000289	CcSEcCtD
Terazosin—Back pain—Epirubicin—prostate cancer	0.00011	0.000288	CcSEcCtD
Terazosin—Feeling abnormal—Capecitabine—prostate cancer	0.00011	0.000288	CcSEcCtD
Terazosin—Dizziness—Etoposide—prostate cancer	0.00011	0.000287	CcSEcCtD
Terazosin—Gastrointestinal pain—Capecitabine—prostate cancer	0.000109	0.000285	CcSEcCtD
Terazosin—Abdominal pain—Docetaxel—prostate cancer	0.000109	0.000285	CcSEcCtD
Terazosin—Body temperature increased—Docetaxel—prostate cancer	0.000109	0.000285	CcSEcCtD
Terazosin—Musculoskeletal discomfort—Prednisone—prostate cancer	0.000109	0.000283	CcSEcCtD
Terazosin—Arrhythmia—Doxorubicin—prostate cancer	0.000108	0.000283	CcSEcCtD
Terazosin—Insomnia—Prednisone—prostate cancer	0.000108	0.000281	CcSEcCtD
Terazosin—Vision blurred—Epirubicin—prostate cancer	0.000108	0.000281	CcSEcCtD
Terazosin—Paraesthesia—Prednisone—prostate cancer	0.000107	0.000279	CcSEcCtD
Terazosin—Ill-defined disorder—Epirubicin—prostate cancer	0.000106	0.000276	CcSEcCtD
Terazosin—Abdominal pain—Capecitabine—prostate cancer	0.000106	0.000276	CcSEcCtD
Terazosin—Body temperature increased—Capecitabine—prostate cancer	0.000106	0.000276	CcSEcCtD
Terazosin—Vomiting—Etoposide—prostate cancer	0.000106	0.000276	CcSEcCtD
Terazosin—Malnutrition—Doxorubicin—prostate cancer	0.000106	0.000276	CcSEcCtD
Terazosin—Dyspepsia—Prednisone—prostate cancer	0.000105	0.000274	CcSEcCtD
Terazosin—Rash—Etoposide—prostate cancer	0.000105	0.000273	CcSEcCtD
Terazosin—Dermatitis—Etoposide—prostate cancer	0.000105	0.000273	CcSEcCtD
Terazosin—Headache—Etoposide—prostate cancer	0.000104	0.000272	CcSEcCtD
Terazosin—Flatulence—Doxorubicin—prostate cancer	0.000104	0.000272	CcSEcCtD
Terazosin—Tension—Doxorubicin—prostate cancer	0.000104	0.00027	CcSEcCtD
Terazosin—Decreased appetite—Prednisone—prostate cancer	0.000104	0.00027	CcSEcCtD
Terazosin—Dysgeusia—Doxorubicin—prostate cancer	0.000103	0.00027	CcSEcCtD
Terazosin—Malaise—Epirubicin—prostate cancer	0.000103	0.000269	CcSEcCtD
Terazosin—Fatigue—Prednisone—prostate cancer	0.000103	0.000268	CcSEcCtD
Terazosin—Nervousness—Doxorubicin—prostate cancer	0.000103	0.000268	CcSEcCtD
Terazosin—Vertigo—Epirubicin—prostate cancer	0.000103	0.000268	CcSEcCtD
Terazosin—Syncope—Epirubicin—prostate cancer	0.000102	0.000267	CcSEcCtD
Terazosin—Back pain—Doxorubicin—prostate cancer	0.000102	0.000267	CcSEcCtD
Terazosin—Constipation—Prednisone—prostate cancer	0.000102	0.000266	CcSEcCtD
Terazosin—Hypersensitivity—Docetaxel—prostate cancer	0.000102	0.000266	CcSEcCtD
Terazosin—Palpitations—Epirubicin—prostate cancer	0.000101	0.000263	CcSEcCtD
Terazosin—Loss of consciousness—Epirubicin—prostate cancer	0.0001	0.000262	CcSEcCtD
Terazosin—Cough—Epirubicin—prostate cancer	9.97e-05	0.00026	CcSEcCtD
Terazosin—Vision blurred—Doxorubicin—prostate cancer	9.96e-05	0.00026	CcSEcCtD
Terazosin—Asthenia—Docetaxel—prostate cancer	9.91e-05	0.000259	CcSEcCtD
Terazosin—Convulsion—Epirubicin—prostate cancer	9.9e-05	0.000258	CcSEcCtD
Terazosin—Nausea—Etoposide—prostate cancer	9.88e-05	0.000258	CcSEcCtD
Terazosin—Hypersensitivity—Capecitabine—prostate cancer	9.86e-05	0.000257	CcSEcCtD
Terazosin—Feeling abnormal—Prednisone—prostate cancer	9.82e-05	0.000256	CcSEcCtD
Terazosin—Ill-defined disorder—Doxorubicin—prostate cancer	9.8e-05	0.000256	CcSEcCtD
Terazosin—Pruritus—Docetaxel—prostate cancer	9.78e-05	0.000255	CcSEcCtD
Terazosin—Gastrointestinal pain—Prednisone—prostate cancer	9.75e-05	0.000254	CcSEcCtD
Terazosin—Chest pain—Epirubicin—prostate cancer	9.72e-05	0.000254	CcSEcCtD
Terazosin—Arthralgia—Epirubicin—prostate cancer	9.72e-05	0.000254	CcSEcCtD
Terazosin—Myalgia—Epirubicin—prostate cancer	9.72e-05	0.000254	CcSEcCtD
Terazosin—Anxiety—Epirubicin—prostate cancer	9.69e-05	0.000253	CcSEcCtD
Terazosin—Discomfort—Epirubicin—prostate cancer	9.61e-05	0.000251	CcSEcCtD
Terazosin—Asthenia—Capecitabine—prostate cancer	9.6e-05	0.00025	CcSEcCtD
Terazosin—Malaise—Doxorubicin—prostate cancer	9.53e-05	0.000249	CcSEcCtD
Terazosin—Dry mouth—Epirubicin—prostate cancer	9.51e-05	0.000248	CcSEcCtD
Terazosin—Vertigo—Doxorubicin—prostate cancer	9.49e-05	0.000248	CcSEcCtD
Terazosin—Syncope—Doxorubicin—prostate cancer	9.48e-05	0.000247	CcSEcCtD
Terazosin—Pruritus—Capecitabine—prostate cancer	9.47e-05	0.000247	CcSEcCtD
Terazosin—Diarrhoea—Docetaxel—prostate cancer	9.46e-05	0.000247	CcSEcCtD
Terazosin—Abdominal pain—Prednisone—prostate cancer	9.42e-05	0.000246	CcSEcCtD
Terazosin—Body temperature increased—Prednisone—prostate cancer	9.42e-05	0.000246	CcSEcCtD
Terazosin—Confusional state—Epirubicin—prostate cancer	9.4e-05	0.000245	CcSEcCtD
Terazosin—Palpitations—Doxorubicin—prostate cancer	9.34e-05	0.000244	CcSEcCtD
Terazosin—Oedema—Epirubicin—prostate cancer	9.32e-05	0.000243	CcSEcCtD
Terazosin—Anaphylactic shock—Epirubicin—prostate cancer	9.32e-05	0.000243	CcSEcCtD
Terazosin—Loss of consciousness—Doxorubicin—prostate cancer	9.29e-05	0.000242	CcSEcCtD
Terazosin—Cough—Doxorubicin—prostate cancer	9.22e-05	0.00024	CcSEcCtD
Terazosin—Shock—Epirubicin—prostate cancer	9.17e-05	0.000239	CcSEcCtD
Terazosin—Convulsion—Doxorubicin—prostate cancer	9.16e-05	0.000239	CcSEcCtD
Terazosin—Diarrhoea—Capecitabine—prostate cancer	9.15e-05	0.000239	CcSEcCtD
Terazosin—Dizziness—Docetaxel—prostate cancer	9.14e-05	0.000238	CcSEcCtD
Terazosin—Thrombocytopenia—Epirubicin—prostate cancer	9.13e-05	0.000238	CcSEcCtD
Terazosin—Tachycardia—Epirubicin—prostate cancer	9.1e-05	0.000237	CcSEcCtD
Terazosin—Hyperhidrosis—Epirubicin—prostate cancer	9.01e-05	0.000235	CcSEcCtD
Terazosin—Chest pain—Doxorubicin—prostate cancer	9e-05	0.000235	CcSEcCtD
Terazosin—Arthralgia—Doxorubicin—prostate cancer	9e-05	0.000235	CcSEcCtD
Terazosin—Myalgia—Doxorubicin—prostate cancer	9e-05	0.000235	CcSEcCtD
Terazosin—Anxiety—Doxorubicin—prostate cancer	8.97e-05	0.000234	CcSEcCtD
Terazosin—Discomfort—Doxorubicin—prostate cancer	8.89e-05	0.000232	CcSEcCtD
Terazosin—Anorexia—Epirubicin—prostate cancer	8.88e-05	0.000232	CcSEcCtD
Terazosin—Dizziness—Capecitabine—prostate cancer	8.85e-05	0.000231	CcSEcCtD
Terazosin—Dry mouth—Doxorubicin—prostate cancer	8.8e-05	0.000229	CcSEcCtD
Terazosin—Vomiting—Docetaxel—prostate cancer	8.79e-05	0.000229	CcSEcCtD
Terazosin—Hypersensitivity—Prednisone—prostate cancer	8.78e-05	0.000229	CcSEcCtD
Terazosin—Rash—Docetaxel—prostate cancer	8.71e-05	0.000227	CcSEcCtD
Terazosin—Hypotension—Epirubicin—prostate cancer	8.71e-05	0.000227	CcSEcCtD
Terazosin—Dermatitis—Docetaxel—prostate cancer	8.71e-05	0.000227	CcSEcCtD
Terazosin—Confusional state—Doxorubicin—prostate cancer	8.7e-05	0.000227	CcSEcCtD
Terazosin—Headache—Docetaxel—prostate cancer	8.66e-05	0.000226	CcSEcCtD
Terazosin—Anaphylactic shock—Doxorubicin—prostate cancer	8.62e-05	0.000225	CcSEcCtD
Terazosin—Oedema—Doxorubicin—prostate cancer	8.62e-05	0.000225	CcSEcCtD
Terazosin—Asthenia—Prednisone—prostate cancer	8.55e-05	0.000223	CcSEcCtD
Terazosin—Vomiting—Capecitabine—prostate cancer	8.51e-05	0.000222	CcSEcCtD
Terazosin—Musculoskeletal discomfort—Epirubicin—prostate cancer	8.49e-05	0.000221	CcSEcCtD
Terazosin—Shock—Doxorubicin—prostate cancer	8.49e-05	0.000221	CcSEcCtD
Terazosin—Thrombocytopenia—Doxorubicin—prostate cancer	8.44e-05	0.00022	CcSEcCtD
Terazosin—Rash—Capecitabine—prostate cancer	8.44e-05	0.00022	CcSEcCtD
Terazosin—Pruritus—Prednisone—prostate cancer	8.43e-05	0.00022	CcSEcCtD
Terazosin—Insomnia—Epirubicin—prostate cancer	8.43e-05	0.00022	CcSEcCtD
Terazosin—Dermatitis—Capecitabine—prostate cancer	8.43e-05	0.00022	CcSEcCtD
Terazosin—Tachycardia—Doxorubicin—prostate cancer	8.42e-05	0.00022	CcSEcCtD
Terazosin—Headache—Capecitabine—prostate cancer	8.38e-05	0.000219	CcSEcCtD
Terazosin—Paraesthesia—Epirubicin—prostate cancer	8.37e-05	0.000218	CcSEcCtD
Terazosin—Hyperhidrosis—Doxorubicin—prostate cancer	8.34e-05	0.000217	CcSEcCtD
Terazosin—Dyspnoea—Epirubicin—prostate cancer	8.31e-05	0.000217	CcSEcCtD
Terazosin—Somnolence—Epirubicin—prostate cancer	8.29e-05	0.000216	CcSEcCtD
Terazosin—Anorexia—Doxorubicin—prostate cancer	8.22e-05	0.000214	CcSEcCtD
Terazosin—Nausea—Docetaxel—prostate cancer	8.21e-05	0.000214	CcSEcCtD
Terazosin—Dyspepsia—Epirubicin—prostate cancer	8.2e-05	0.000214	CcSEcCtD
Terazosin—Diarrhoea—Prednisone—prostate cancer	8.15e-05	0.000213	CcSEcCtD
Terazosin—Decreased appetite—Epirubicin—prostate cancer	8.1e-05	0.000211	CcSEcCtD
Terazosin—Hypotension—Doxorubicin—prostate cancer	8.06e-05	0.00021	CcSEcCtD
Terazosin—Fatigue—Epirubicin—prostate cancer	8.04e-05	0.00021	CcSEcCtD
Terazosin—Constipation—Epirubicin—prostate cancer	7.97e-05	0.000208	CcSEcCtD
Terazosin—Pain—Epirubicin—prostate cancer	7.97e-05	0.000208	CcSEcCtD
Terazosin—Nausea—Capecitabine—prostate cancer	7.95e-05	0.000207	CcSEcCtD
Terazosin—Dizziness—Prednisone—prostate cancer	7.88e-05	0.000206	CcSEcCtD
Terazosin—Musculoskeletal discomfort—Doxorubicin—prostate cancer	7.86e-05	0.000205	CcSEcCtD
Terazosin—Insomnia—Doxorubicin—prostate cancer	7.8e-05	0.000203	CcSEcCtD
Terazosin—Paraesthesia—Doxorubicin—prostate cancer	7.74e-05	0.000202	CcSEcCtD
Terazosin—Dyspnoea—Doxorubicin—prostate cancer	7.69e-05	0.000201	CcSEcCtD
Terazosin—Feeling abnormal—Epirubicin—prostate cancer	7.68e-05	0.0002	CcSEcCtD
Terazosin—Somnolence—Doxorubicin—prostate cancer	7.67e-05	0.0002	CcSEcCtD
Terazosin—Gastrointestinal pain—Epirubicin—prostate cancer	7.62e-05	0.000199	CcSEcCtD
Terazosin—Dyspepsia—Doxorubicin—prostate cancer	7.59e-05	0.000198	CcSEcCtD
Terazosin—Vomiting—Prednisone—prostate cancer	7.58e-05	0.000198	CcSEcCtD
Terazosin—Rash—Prednisone—prostate cancer	7.51e-05	0.000196	CcSEcCtD
Terazosin—Dermatitis—Prednisone—prostate cancer	7.51e-05	0.000196	CcSEcCtD
Terazosin—Decreased appetite—Doxorubicin—prostate cancer	7.5e-05	0.000196	CcSEcCtD
Terazosin—Headache—Prednisone—prostate cancer	7.47e-05	0.000195	CcSEcCtD
Terazosin—Fatigue—Doxorubicin—prostate cancer	7.44e-05	0.000194	CcSEcCtD
Terazosin—Constipation—Doxorubicin—prostate cancer	7.38e-05	0.000192	CcSEcCtD
Terazosin—Pain—Doxorubicin—prostate cancer	7.38e-05	0.000192	CcSEcCtD
Terazosin—Body temperature increased—Epirubicin—prostate cancer	7.37e-05	0.000192	CcSEcCtD
Terazosin—Abdominal pain—Epirubicin—prostate cancer	7.37e-05	0.000192	CcSEcCtD
Terazosin—Feeling abnormal—Doxorubicin—prostate cancer	7.11e-05	0.000185	CcSEcCtD
Terazosin—Nausea—Prednisone—prostate cancer	7.08e-05	0.000185	CcSEcCtD
Terazosin—Gastrointestinal pain—Doxorubicin—prostate cancer	7.05e-05	0.000184	CcSEcCtD
Terazosin—Hypersensitivity—Epirubicin—prostate cancer	6.87e-05	0.000179	CcSEcCtD
Terazosin—Body temperature increased—Doxorubicin—prostate cancer	6.82e-05	0.000178	CcSEcCtD
Terazosin—Abdominal pain—Doxorubicin—prostate cancer	6.82e-05	0.000178	CcSEcCtD
Terazosin—Asthenia—Epirubicin—prostate cancer	6.69e-05	0.000174	CcSEcCtD
Terazosin—Pruritus—Epirubicin—prostate cancer	6.59e-05	0.000172	CcSEcCtD
Terazosin—Diarrhoea—Epirubicin—prostate cancer	6.38e-05	0.000166	CcSEcCtD
Terazosin—Hypersensitivity—Doxorubicin—prostate cancer	6.35e-05	0.000166	CcSEcCtD
Terazosin—Asthenia—Doxorubicin—prostate cancer	6.19e-05	0.000161	CcSEcCtD
Terazosin—Dizziness—Epirubicin—prostate cancer	6.16e-05	0.000161	CcSEcCtD
Terazosin—Pruritus—Doxorubicin—prostate cancer	6.1e-05	0.000159	CcSEcCtD
Terazosin—Vomiting—Epirubicin—prostate cancer	5.93e-05	0.000155	CcSEcCtD
Terazosin—Diarrhoea—Doxorubicin—prostate cancer	5.9e-05	0.000154	CcSEcCtD
Terazosin—Rash—Epirubicin—prostate cancer	5.88e-05	0.000153	CcSEcCtD
Terazosin—Dermatitis—Epirubicin—prostate cancer	5.87e-05	0.000153	CcSEcCtD
Terazosin—Headache—Epirubicin—prostate cancer	5.84e-05	0.000152	CcSEcCtD
Terazosin—Dizziness—Doxorubicin—prostate cancer	5.7e-05	0.000149	CcSEcCtD
Terazosin—Nausea—Epirubicin—prostate cancer	5.54e-05	0.000144	CcSEcCtD
Terazosin—Vomiting—Doxorubicin—prostate cancer	5.48e-05	0.000143	CcSEcCtD
Terazosin—Rash—Doxorubicin—prostate cancer	5.44e-05	0.000142	CcSEcCtD
Terazosin—Dermatitis—Doxorubicin—prostate cancer	5.43e-05	0.000142	CcSEcCtD
Terazosin—Headache—Doxorubicin—prostate cancer	5.4e-05	0.000141	CcSEcCtD
Terazosin—Nausea—Doxorubicin—prostate cancer	5.12e-05	0.000134	CcSEcCtD
Terazosin—ADRA1B—Signaling Pathways—ADRB2—prostate cancer	1.35e-05	0.00013	CbGpPWpGaD
Terazosin—ADRA1B—GPCR downstream signaling—JAK2—prostate cancer	1.33e-05	0.000128	CbGpPWpGaD
Terazosin—ADRA1A—Signaling by GPCR—PIK3CG—prostate cancer	1.33e-05	0.000128	CbGpPWpGaD
Terazosin—ADRA1D—Signaling by GPCR—CXCL8—prostate cancer	1.33e-05	0.000128	CbGpPWpGaD
Terazosin—ADRA1B—Signaling by GPCR—MAP2K1—prostate cancer	1.32e-05	0.000127	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—ERBB3—prostate cancer	1.32e-05	0.000127	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—FGFR2—prostate cancer	1.32e-05	0.000127	CbGpPWpGaD
Terazosin—ADRA1B—Signaling by GPCR—PIK3CD—prostate cancer	1.32e-05	0.000127	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—HPGDS—prostate cancer	1.32e-05	0.000126	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—VAV3—prostate cancer	1.31e-05	0.000126	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—CASP9—prostate cancer	1.31e-05	0.000126	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—CYP2C19—prostate cancer	1.31e-05	0.000126	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—TGFBR2—prostate cancer	1.3e-05	0.000125	CbGpPWpGaD
Terazosin—ADRA1A—GPCR downstream signaling—PIK3CD—prostate cancer	1.29e-05	0.000124	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—GSTT1—prostate cancer	1.28e-05	0.000123	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—ACHE—prostate cancer	1.28e-05	0.000123	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—ITPR1—prostate cancer	1.27e-05	0.000123	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—PRKCQ—prostate cancer	1.27e-05	0.000122	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—NGFR—prostate cancer	1.27e-05	0.000122	CbGpPWpGaD
Terazosin—ADRA1D—Signaling by GPCR—IL2—prostate cancer	1.27e-05	0.000122	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—TERT—prostate cancer	1.26e-05	0.000122	CbGpPWpGaD
Terazosin—ADRA1B—GPCR downstream signaling—PIK3CB—prostate cancer	1.26e-05	0.000121	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—CYP2A6—prostate cancer	1.26e-05	0.000121	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—MAP3K7—prostate cancer	1.26e-05	0.000121	CbGpPWpGaD
Terazosin—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—prostate cancer	1.24e-05	0.000119	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—AKR1C3—prostate cancer	1.23e-05	0.000118	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—PRKACB—prostate cancer	1.22e-05	0.000117	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—IGF1R—prostate cancer	1.22e-05	0.000117	CbGpPWpGaD
Terazosin—ADRA1B—GPCR downstream signaling—CXCL8—prostate cancer	1.21e-05	0.000117	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—FGF10—prostate cancer	1.21e-05	0.000116	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—HIF1A—prostate cancer	1.21e-05	0.000116	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—CYP17A1—prostate cancer	1.21e-05	0.000116	CbGpPWpGaD
Terazosin—ADRA1B—Signaling by GPCR—JAK2—prostate cancer	1.21e-05	0.000116	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—ADRB2—prostate cancer	1.2e-05	0.000115	CbGpPWpGaD
Terazosin—ABCB1—Transmembrane transport of small molecules—CREBBP—prostate cancer	1.19e-05	0.000115	CbGpPWpGaD
Terazosin—ADRA1A—GPCR downstream signaling—JAK2—prostate cancer	1.18e-05	0.000114	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—LEP—prostate cancer	1.18e-05	0.000113	CbGpPWpGaD
Terazosin—ADRA1A—Signaling by GPCR—MAP2K1—prostate cancer	1.18e-05	0.000113	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—CAV1—prostate cancer	1.17e-05	0.000112	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—LPL—prostate cancer	1.17e-05	0.000112	CbGpPWpGaD
Terazosin—ADRA1A—Signaling by GPCR—PIK3CD—prostate cancer	1.17e-05	0.000112	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—VAV3—prostate cancer	1.17e-05	0.000112	CbGpPWpGaD
Terazosin—ADRA1B—GPCR downstream signaling—IL2—prostate cancer	1.16e-05	0.000112	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—PDGFRB—prostate cancer	1.16e-05	0.000111	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—KDR—prostate cancer	1.16e-05	0.000111	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—TGFBR2—prostate cancer	1.15e-05	0.000111	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—NCOA2—prostate cancer	1.15e-05	0.000111	CbGpPWpGaD
Terazosin—ADRA1B—Signaling by GPCR—PIK3CB—prostate cancer	1.15e-05	0.00011	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—ITPR1—prostate cancer	1.13e-05	0.000109	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—ITGB3—prostate cancer	1.13e-05	0.000109	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—ESR1—prostate cancer	1.13e-05	0.000108	CbGpPWpGaD
Terazosin—ADRA1A—GPCR downstream signaling—PIK3CB—prostate cancer	1.12e-05	0.000108	CbGpPWpGaD
Terazosin—ADRA1B—Signaling by GPCR—CXCL8—prostate cancer	1.1e-05	0.000106	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—BAD—prostate cancer	1.1e-05	0.000106	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—SLC5A5—prostate cancer	1.1e-05	0.000106	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—ERBB3—prostate cancer	1.09e-05	0.000105	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—FGFR2—prostate cancer	1.09e-05	0.000105	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—IGF1R—prostate cancer	1.08e-05	0.000104	CbGpPWpGaD
Terazosin—ADRA1A—GPCR downstream signaling—CXCL8—prostate cancer	1.08e-05	0.000104	CbGpPWpGaD
Terazosin—ADRA1A—Signaling by GPCR—JAK2—prostate cancer	1.07e-05	0.000103	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—CYP2E1—prostate cancer	1.07e-05	0.000103	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—PIK3CG—prostate cancer	1.07e-05	0.000102	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—APC—prostate cancer	1.07e-05	0.000102	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—NQO1—prostate cancer	1.06e-05	0.000102	CbGpPWpGaD
Terazosin—ADRA1B—Signaling by GPCR—IL2—prostate cancer	1.05e-05	0.000101	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—IRS1—prostate cancer	1.05e-05	0.000101	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—EGF—prostate cancer	1.05e-05	0.000101	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—TERT—prostate cancer	1.05e-05	0.000101	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—TH—prostate cancer	1.04e-05	0.0001	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—LPL—prostate cancer	1.04e-05	9.98e-05	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—CYP3A4—prostate cancer	1.03e-05	9.94e-05	CbGpPWpGaD
Terazosin—ADRA1A—GPCR downstream signaling—IL2—prostate cancer	1.03e-05	9.91e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—PDGFRB—prostate cancer	1.03e-05	9.89e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—GSK3B—prostate cancer	1.02e-05	9.83e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling by GPCR—PIK3CB—prostate cancer	1.02e-05	9.79e-05	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—CYP1B1—prostate cancer	1.02e-05	9.77e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—INS—prostate cancer	1.01e-05	9.7e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—HIF1A—prostate cancer	1e-05	9.65e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—ITGB3—prostate cancer	1e-05	9.64e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—CREBBP—prostate cancer	9.87e-06	9.5e-05	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—GGT1—prostate cancer	9.84e-06	9.47e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—LEP—prostate cancer	9.79e-06	9.42e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling by GPCR—CXCL8—prostate cancer	9.79e-06	9.41e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—IGF1—prostate cancer	9.75e-06	9.38e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—ERBB3—prostate cancer	9.72e-06	9.35e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—FGFR2—prostate cancer	9.71e-06	9.34e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—CAV1—prostate cancer	9.7e-06	9.33e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling by GPCR—EGFR—prostate cancer	9.7e-06	9.33e-05	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—NCOA1—prostate cancer	9.7e-06	9.32e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—KDR—prostate cancer	9.6e-06	9.23e-05	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—CYP19A1—prostate cancer	9.56e-06	9.19e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—MAP2K1—prostate cancer	9.42e-06	9.06e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—PIK3CD—prostate cancer	9.36e-06	9e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling by GPCR—IL2—prostate cancer	9.35e-06	9e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—ESR1—prostate cancer	9.35e-06	8.99e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—TERT—prostate cancer	9.32e-06	8.96e-05	CbGpPWpGaD
Terazosin—ADRA1D—GPCR downstream signaling—PIK3CA—prostate cancer	9.27e-06	8.92e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—SERPINE1—prostate cancer	9.26e-06	8.91e-05	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—RXRA—prostate cancer	9.22e-06	8.87e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling by GPCR—KRAS—prostate cancer	9.17e-06	8.82e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—BAD—prostate cancer	9.13e-06	8.78e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—FGF2—prostate cancer	8.96e-06	8.62e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—HIF1A—prostate cancer	8.91e-06	8.57e-05	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—COMT—prostate cancer	8.88e-06	8.54e-05	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—GSTP1—prostate cancer	8.84e-06	8.5e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—NOS3—prostate cancer	8.84e-06	8.5e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—PIK3CG—prostate cancer	8.84e-06	8.5e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—APC—prostate cancer	8.84e-06	8.5e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—EGF—prostate cancer	8.74e-06	8.4e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—IRS1—prostate cancer	8.74e-06	8.4e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—LEP—prostate cancer	8.7e-06	8.37e-05	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—ITPR1—prostate cancer	8.7e-06	8.37e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—CAV1—prostate cancer	8.62e-06	8.29e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—JAK2—prostate cancer	8.59e-06	8.26e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—KDR—prostate cancer	8.52e-06	8.2e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—GSK3B—prostate cancer	8.48e-06	8.16e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling by GPCR—PIK3CA—prostate cancer	8.42e-06	8.1e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—MDM2—prostate cancer	8.39e-06	8.07e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—INS—prostate cancer	8.37e-06	8.05e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—ESR1—prostate cancer	8.31e-06	7.99e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—ERBB2—prostate cancer	8.27e-06	7.95e-05	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—TYMS—prostate cancer	8.22e-06	7.9e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—CREBBP—prostate cancer	8.2e-06	7.88e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—PIK3CB—prostate cancer	8.16e-06	7.85e-05	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—GSTM1—prostate cancer	8.12e-06	7.81e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—BAD—prostate cancer	8.11e-06	7.8e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—IGF1—prostate cancer	8.09e-06	7.78e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling by GPCR—EGFR—prostate cancer	8.05e-06	7.74e-05	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—LPL—prostate cancer	7.97e-06	7.67e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—APC—prostate cancer	7.85e-06	7.55e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—PIK3CG—prostate cancer	7.85e-06	7.55e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—CXCL8—prostate cancer	7.84e-06	7.54e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—MAP2K1—prostate cancer	7.82e-06	7.52e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—PIK3CD—prostate cancer	7.77e-06	7.47e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—EGF—prostate cancer	7.76e-06	7.46e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—IRS1—prostate cancer	7.76e-06	7.46e-05	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—CYP1A1—prostate cancer	7.7e-06	7.41e-05	CbGpPWpGaD
Terazosin—ADRA1B—GPCR downstream signaling—PIK3CA—prostate cancer	7.7e-06	7.4e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—SERPINE1—prostate cancer	7.69e-06	7.39e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—CDKN1B—prostate cancer	7.66e-06	7.37e-05	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—ERCC2—prostate cancer	7.64e-06	7.35e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling by GPCR—KRAS—prostate cancer	7.61e-06	7.32e-05	CbGpPWpGaD
Terazosin—ADRA1D—GPCR downstream signaling—AKT1—prostate cancer	7.58e-06	7.29e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—GSK3B—prostate cancer	7.53e-06	7.25e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—CASP3—prostate cancer	7.51e-06	7.22e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—IL2—prostate cancer	7.49e-06	7.21e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling by GPCR—IL6—prostate cancer	7.46e-06	7.17e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—FGF2—prostate cancer	7.44e-06	7.16e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—INS—prostate cancer	7.43e-06	7.15e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—NOS3—prostate cancer	7.34e-06	7.06e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—CCND1—prostate cancer	7.31e-06	7.03e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—CREBBP—prostate cancer	7.28e-06	7e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—CTNNB1—prostate cancer	7.23e-06	6.96e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—IGF1—prostate cancer	7.19e-06	6.91e-05	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—MTHFR—prostate cancer	7.18e-06	6.91e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling by GPCR—EGFR—prostate cancer	7.15e-06	6.88e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—JAK2—prostate cancer	7.13e-06	6.86e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—MMP9—prostate cancer	7.09e-06	6.82e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—CDKN1A—prostate cancer	7.07e-06	6.8e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—PTEN—prostate cancer	7.05e-06	6.78e-05	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—PPARA—prostate cancer	7.04e-06	6.77e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling by GPCR—PIK3CA—prostate cancer	6.99e-06	6.72e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—MDM2—prostate cancer	6.96e-06	6.7e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—MAP2K1—prostate cancer	6.95e-06	6.68e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—PIK3CD—prostate cancer	6.9e-06	6.64e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling by GPCR—AKT1—prostate cancer	6.88e-06	6.62e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—ERBB2—prostate cancer	6.86e-06	6.6e-05	CbGpPWpGaD
Terazosin—ADRA1A—GPCR downstream signaling—PIK3CA—prostate cancer	6.84e-06	6.57e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—SERPINE1—prostate cancer	6.83e-06	6.57e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—PIK3CB—prostate cancer	6.77e-06	6.51e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling by GPCR—KRAS—prostate cancer	6.76e-06	6.5e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—EP300—prostate cancer	6.72e-06	6.47e-05	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—CAV1—prostate cancer	6.62e-06	6.37e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—FGF2—prostate cancer	6.61e-06	6.36e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—SRC—prostate cancer	6.54e-06	6.29e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—NOS3—prostate cancer	6.52e-06	6.27e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—CXCL8—prostate cancer	6.51e-06	6.26e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—VEGFA—prostate cancer	6.37e-06	6.13e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—CDKN1B—prostate cancer	6.36e-06	6.11e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—JAK2—prostate cancer	6.33e-06	6.09e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—STAT3—prostate cancer	6.31e-06	6.07e-05	CbGpPWpGaD
Terazosin—ADRA1B—GPCR downstream signaling—AKT1—prostate cancer	6.29e-06	6.05e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—CASP3—prostate cancer	6.23e-06	5.99e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—IL2—prostate cancer	6.22e-06	5.98e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling by GPCR—PIK3CA—prostate cancer	6.21e-06	5.97e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling by GPCR—IL6—prostate cancer	6.19e-06	5.95e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—MDM2—prostate cancer	6.18e-06	5.95e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—ERBB2—prostate cancer	6.1e-06	5.86e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—CCND1—prostate cancer	6.06e-06	5.83e-05	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—PIK3CG—prostate cancer	6.03e-06	5.8e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—PIK3CB—prostate cancer	6.02e-06	5.79e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—CTNNB1—prostate cancer	6e-06	5.78e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—MMP9—prostate cancer	5.89e-06	5.66e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—CDKN1A—prostate cancer	5.87e-06	5.64e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—MYC—prostate cancer	5.86e-06	5.64e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—PTEN—prostate cancer	5.85e-06	5.63e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—TGFB1—prostate cancer	5.85e-06	5.62e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—CXCL8—prostate cancer	5.78e-06	5.56e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—EGFR—prostate cancer	5.73e-06	5.51e-05	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—INS—prostate cancer	5.71e-06	5.49e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling by GPCR—AKT1—prostate cancer	5.71e-06	5.49e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—CDKN1B—prostate cancer	5.65e-06	5.43e-05	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—CREBBP—prostate cancer	5.59e-06	5.38e-05	CbGpPWpGaD
Terazosin—ADRA1A—GPCR downstream signaling—AKT1—prostate cancer	5.58e-06	5.37e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—EP300—prostate cancer	5.58e-06	5.37e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—CASP3—prostate cancer	5.53e-06	5.32e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—IL2—prostate cancer	5.53e-06	5.31e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling by GPCR—IL6—prostate cancer	5.5e-06	5.29e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—SRC—prostate cancer	5.43e-06	5.22e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—KRAS—prostate cancer	5.41e-06	5.21e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—CCND1—prostate cancer	5.39e-06	5.18e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—CTNNB1—prostate cancer	5.33e-06	5.13e-05	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—PIK3CD—prostate cancer	5.3e-06	5.1e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—VEGFA—prostate cancer	5.29e-06	5.08e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—STAT3—prostate cancer	5.23e-06	5.03e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—MMP9—prostate cancer	5.23e-06	5.03e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—CDKN1A—prostate cancer	5.21e-06	5.01e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—PTEN—prostate cancer	5.2e-06	5e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling by GPCR—AKT1—prostate cancer	5.07e-06	4.88e-05	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—NOS3—prostate cancer	5.01e-06	4.82e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—PIK3CA—prostate cancer	4.97e-06	4.78e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—EP300—prostate cancer	4.96e-06	4.77e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—MYC—prostate cancer	4.86e-06	4.68e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—TGFB1—prostate cancer	4.85e-06	4.67e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—SRC—prostate cancer	4.82e-06	4.64e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—TP53—prostate cancer	4.81e-06	4.63e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—EGFR—prostate cancer	4.76e-06	4.58e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—VEGFA—prostate cancer	4.7e-06	4.52e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—STAT3—prostate cancer	4.65e-06	4.47e-05	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—PIK3CB—prostate cancer	4.62e-06	4.45e-05	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—PTGS2—prostate cancer	4.58e-06	4.41e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—KRAS—prostate cancer	4.49e-06	4.32e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—IL6—prostate cancer	4.41e-06	4.24e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—MYC—prostate cancer	4.32e-06	4.15e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—TGFB1—prostate cancer	4.31e-06	4.14e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—EGFR—prostate cancer	4.23e-06	4.06e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—PIK3CA—prostate cancer	4.13e-06	3.97e-05	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—AKT1—prostate cancer	4.06e-06	3.91e-05	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—PTEN—prostate cancer	3.99e-06	3.84e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—TP53—prostate cancer	3.99e-06	3.84e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—KRAS—prostate cancer	3.99e-06	3.84e-05	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—EP300—prostate cancer	3.81e-06	3.66e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—PIK3CA—prostate cancer	3.67e-06	3.53e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—IL6—prostate cancer	3.66e-06	3.52e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—TP53—prostate cancer	3.55e-06	3.41e-05	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—AKT1—prostate cancer	3.37e-06	3.24e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—IL6—prostate cancer	3.25e-06	3.12e-05	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—AKT1—prostate cancer	3e-06	2.88e-05	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—PIK3CA—prostate cancer	2.82e-06	2.71e-05	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—AKT1—prostate cancer	2.3e-06	2.21e-05	CbGpPWpGaD
